MA32705B1 - Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation - Google Patents
Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisationInfo
- Publication number
- MA32705B1 MA32705B1 MA33762A MA33762A MA32705B1 MA 32705 B1 MA32705 B1 MA 32705B1 MA 33762 A MA33762 A MA 33762A MA 33762 A MA33762 A MA 33762A MA 32705 B1 MA32705 B1 MA 32705B1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- compounds
- secretase
- disorders
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA PRÉSENTE INVENTION PORTE SUR UNE NOUVELLE CLASSE DE COMPOSÉS UTILES POUR LA MODULATION DE L'ACTIVITÉ DE L'ENZYME BÊTA-SÉCRÉTASE ET POUR LE TRAITEMENT DE MALADIES À MÉDIATION PAR LA BÊTA-SÉCRÉTASE, DONT LA MALADIE D'ALZHEIMER (MA) ET LES AFFECTIONS APPARENTÉES. DANS UN MODE DE RÉALISATION, LES COMPOSÉS SONT REPRÉSENTÉS PAR UNE FORMULE GÉNÉRALE (I); DANS LAQUELLE A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y ET Z SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. L'INVENTION PORTE ÉGALEMENT SUR L'UTILISATION DE CES COMPOSÉS DANS DES COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT, PROPHYLACTIQUE OU THÉRAPEUTIQUE, DE TROUBLES ET D'AFFECTIONS LIÉS À L'ACTIVITÉ DE LA PROTÉINE BÊTA-SÉCRÉTASE. DE TELS TROUBLES COMPRENNENT, PAR EXEMPLE, LA MALADIE D'ALZHEIMER, DES DÉFICITS INTELLECTUELS, UNE DÉFICIENCE COGNITIVE, LA SCHIZOPHRÉNIE ET D'AUTRES MALADIES DU SYSTÈME NERVEUX CENTRAL LIÉES À LA FORMATION ET/OU AU DÉPÔT DE PLAQUES AU NIVEAU DU CERVEAU ET/OU PROVOQUÉES PAR LA FORMATION ET/OU LE DÉPÔT DE PLAQUES AU NIVEAU DU CERVEAU. L'INVENTION PORTE ÉGALEMENT SUR D'AUTRES MODES DE RÉALISATION DE LA FORMULE (I), SUR DES INTERMÉDIAIRES ET DES PROCÉDÉS UTILES POUR LA PRÉPARATION DE COMPOSÉS DE FORMULE (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9608208P | 2008-09-11 | 2008-09-11 | |
PCT/US2009/056748 WO2010030954A1 (fr) | 2008-09-11 | 2009-09-11 | Composés cycliques spiro-tétracycliques utiles en tant que modulateurs de la bêta-sécrétase et leurs procédés d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32705B1 true MA32705B1 (fr) | 2011-10-02 |
Family
ID=41319591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33762A MA32705B1 (fr) | 2008-09-11 | 2011-04-11 | Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation |
Country Status (21)
Country | Link |
---|---|
US (1) | US8426447B2 (fr) |
EP (1) | EP2328903B1 (fr) |
JP (1) | JP5579720B2 (fr) |
KR (1) | KR20110073511A (fr) |
CN (1) | CN102209721A (fr) |
AU (1) | AU2009291602B2 (fr) |
BR (1) | BRPI0918449A2 (fr) |
CA (1) | CA2736130C (fr) |
CL (1) | CL2011000516A1 (fr) |
CO (1) | CO6362014A2 (fr) |
CR (1) | CR20110134A (fr) |
EA (1) | EA201100461A1 (fr) |
ES (1) | ES2459195T3 (fr) |
IL (1) | IL211440A0 (fr) |
MA (1) | MA32705B1 (fr) |
MX (1) | MX2011002705A (fr) |
MY (1) | MY148558A (fr) |
PE (1) | PE20110805A1 (fr) |
TW (1) | TWI385175B (fr) |
WO (1) | WO2010030954A1 (fr) |
ZA (1) | ZA201102674B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP2406240B1 (fr) | 2009-03-13 | 2015-12-23 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la beta-secretase |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
EP2539322B1 (fr) | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-secrétase |
EP2547685A1 (fr) * | 2010-03-15 | 2013-01-23 | Amgen Inc. | Composés spiro tétracycliques en tant que modulateurs de la béta-sécrétase |
MX2012010657A (es) * | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
WO2011130741A1 (fr) * | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Composés pour le traitement de maladies neurodégénératives |
US8921363B2 (en) * | 2010-08-05 | 2014-12-30 | Amgen Inc. | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors |
EP2609081A1 (fr) | 2010-08-23 | 2013-07-03 | Amgen Inc. | Dérivés de sulfonylpipérazine qui interagissent avec la protéine régulatrice de la glucokinase pour le traitement du diabète |
CN103221407A (zh) * | 2010-11-22 | 2013-07-24 | 出光兴产株式会社 | 含氧稠环衍生物和含有其而成的有机电致发光元件 |
TW201307357A (zh) * | 2010-11-22 | 2013-02-16 | Array Biopharma Inc | 治療神經退化性疾病之化合物 |
EP2643325A1 (fr) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolones et spiro-amino-dihydro-pyrimidinones en tant que modulateurs de bêta-sécrétase et leurs méthodes d'utilisation |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
EP2673279A1 (fr) | 2011-02-07 | 2013-12-18 | Amgen Inc. | Composés de 5-amino-oxazépine et 5-amino-thiazépane en tant qu'antagonistes de la bêta-sécrétase et leurs procédés d'utilisation |
US8962859B2 (en) | 2011-02-15 | 2015-02-24 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
WO2012168175A1 (fr) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
WO2013044092A1 (fr) * | 2011-09-21 | 2013-03-28 | Amgen Inc. | Composés d'amino-oxazines et d'amino-dihydrothiazine comme modulateurs de sécrétase bêta et procédés d'utilisation |
ES2566373T3 (es) * | 2011-10-10 | 2016-04-12 | Astrazeneca Ab | Inhibidores monofluoro beta-secretasa |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
EP2650284A1 (fr) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique |
JP2015518048A (ja) * | 2012-05-30 | 2015-06-25 | コメンティス, インコーポレイテッド | クロマン化合物 |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US10548882B2 (en) | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
JP2015532282A (ja) | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | β−セクレターゼの阻害剤 |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
AU2016215432B2 (en) | 2015-02-02 | 2020-07-30 | Valo Early Discovery, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2683718A (en) * | 1952-01-11 | 1954-07-13 | Searle & Co | Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione |
US3185696A (en) * | 1959-03-12 | 1965-05-25 | Jack M Tien | 3', 6'-diaminofluoran derivatives of gamma-lactam |
FR2576178B1 (fr) | 1985-01-24 | 1987-04-17 | Furodet Philippe | Procede de fabrication pour un enfumoir a chargement par-dessous |
DE3601492A1 (de) | 1986-01-20 | 1987-07-23 | Vacuumschmelze Gmbh | Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
WO1996040885A2 (fr) | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | β-SECRETASE, ANTICORPS DIRIGES CONTRE LA β-SECRETASE ET DOSAGES PERMETTANT DE DETECTER L'INHIBITION DE LA β-SECRETASE |
KR100866676B1 (ko) | 1998-09-24 | 2008-11-11 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
CA2452039A1 (fr) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Derives de beta-hydroxyamine utiles dans le traitement de la maladie d'alzheimer |
KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
WO2003006013A1 (fr) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Diaminediols pour le traitement de la maladie d'alzheimer |
BR0211122A (pt) | 2001-07-10 | 2004-10-26 | Elan Pharm Inc | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal |
US20030109559A1 (en) | 2001-07-11 | 2003-06-12 | Andrea Gailunas | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds |
BR0213139A (pt) | 2001-10-04 | 2004-08-10 | Elan Pharm Inc | Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica |
JP2005508940A (ja) | 2001-10-05 | 2005-04-07 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用なアリルアミド |
CA2465316A1 (fr) | 2001-10-29 | 2003-05-08 | James P. Beck | Amides a substitution hydroxy pour le traitement de la maladie d'alzheimer |
NZ533107A (en) | 2001-11-08 | 2007-04-27 | Upjohn Co | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
BR0214736A (pt) | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
WO2003057721A2 (fr) | 2002-01-04 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Amino carboxamides substitues destines au traitement de la maladie d'alzheimer |
BR0306982A (pt) | 2002-01-17 | 2004-10-26 | Neurogen Corp | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto |
US7115652B2 (en) | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
AU2003276047A1 (en) | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
DE60315664D1 (de) | 2002-06-20 | 2007-09-27 | Pharmacia & Upjohn Co Llc | Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten |
UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
EP1562897B1 (fr) | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer |
GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
EP1583750B1 (fr) | 2003-01-07 | 2013-02-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de bêta-sécrétase macrocyclique pour traiter la maladie d'Alzheimer |
GB0305918D0 (en) | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
JP2006520371A (ja) | 2003-03-14 | 2006-09-07 | メルク シャープ エンド ドーム リミテッド | 軽症の認識損傷の治療方法及びアルツハイマー病の予防又は遅延方法 |
AR044043A1 (es) | 2003-04-21 | 2005-08-24 | Elan Pharm Inc | Fenacilo 2-hidroxi-3-diaminoalcanos |
CA2523232A1 (fr) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | Benzamide 2-hydroxy-3-diaminoalcanes |
EP1641748B1 (fr) | 2003-06-30 | 2013-08-28 | Merck Sharp & Dohme Corp. | Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer |
CA2530006A1 (fr) | 2003-07-01 | 2005-01-20 | Merck & Co., Inc. | Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
MY149978A (en) | 2003-12-15 | 2013-11-15 | Merck Sharp & Dohme | Heterocyclic aspartyl protease inhibitors |
GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
WO2005097767A1 (fr) | 2004-03-30 | 2005-10-20 | Merck & Co., Inc. | Composes de 2-aminothiazole utiles en tant qu'inhibiteurs de l'aspartyle-protease |
BRPI0512213A (pt) | 2004-06-16 | 2008-02-19 | Wyeth Corp | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto |
WO2006041404A1 (fr) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Composes amino substitues et utilisation de ces compose |
AU2006205127A1 (en) | 2005-01-14 | 2006-07-20 | Wyeth | Amino-imidazolones for the inhibition of beta-secretase |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
JP2008543846A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | プロテアーゼ阻害剤として化合物の調製およびその使用 |
MX2007016183A (es) | 2005-06-14 | 2008-03-10 | Schering Corp | Preparacion y uso de compuestos como inhibidores de proteasas. |
TW200716134A (en) * | 2005-06-16 | 2007-05-01 | Janssen Pharmaceutica Nv | Tricyclic opioid modulators |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
US20070020316A1 (en) * | 2005-07-13 | 2007-01-25 | Raviv Laor | Personal topical disinfectant device |
WO2007011810A1 (fr) | 2005-07-18 | 2007-01-25 | Merck & Co., Inc. | Inhibiteurs de beta-secretase de spiropiperidine destines au traitement de la maladie d'alzheimer |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
WO2007038271A1 (fr) | 2005-09-26 | 2007-04-05 | Wyeth | Composes d'amino-5-[4-(difluoromethoxy) phenyl]-5-phenylimidazolone utilises comme inhibiteurs de la beta-secretase (bace) |
US8173642B2 (en) | 2005-10-25 | 2012-05-08 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
WO2007100536A1 (fr) | 2006-02-24 | 2007-09-07 | Wyeth | COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE |
US20090099217A1 (en) | 2006-04-05 | 2009-04-16 | Astex Therapeutics Ltd. | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
WO2007146225A2 (fr) | 2006-06-12 | 2007-12-21 | Schering Corporation | Inhibiteurs d'aspartyl protéase hétérocycliques |
TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
CA2668065A1 (fr) | 2006-10-30 | 2008-05-08 | Merck & Co., Inc. | Composes de spiropiperidine inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
KR101174191B1 (ko) | 2007-02-02 | 2012-08-14 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료용 taar1 리간드로서 2-아미노옥사졸린 |
CL2008000791A1 (es) | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
UA101352C2 (uk) | 2008-01-18 | 2013-03-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Конденсоване похідне амінодигідротіазину |
CN101952260B (zh) | 2008-02-18 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-*唑-2-基胺衍生物 |
JP2011518224A (ja) | 2008-04-22 | 2011-06-23 | シェーリング コーポレイション | Bace−1阻害剤としてのチオフェニル置換2−イミノ−3−メチルピロロピリミジノン化合物、組成物、およびそれらの使用 |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
KR101307007B1 (ko) | 2008-07-24 | 2013-09-11 | 에프. 호프만-라 로슈 아게 | 4,5-다이하이드로-옥사졸-2-일 유도체 |
CA2731209A1 (fr) * | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Derives de spiroaminodihydrothiazine |
-
2009
- 2009-09-11 MX MX2011002705A patent/MX2011002705A/es active IP Right Grant
- 2009-09-11 PE PE2011000606A patent/PE20110805A1/es not_active Application Discontinuation
- 2009-09-11 US US12/558,426 patent/US8426447B2/en active Active
- 2009-09-11 AU AU2009291602A patent/AU2009291602B2/en not_active Ceased
- 2009-09-11 KR KR1020117008316A patent/KR20110073511A/ko not_active Application Discontinuation
- 2009-09-11 JP JP2011527012A patent/JP5579720B2/ja not_active Expired - Fee Related
- 2009-09-11 ES ES09737222.1T patent/ES2459195T3/es active Active
- 2009-09-11 EP EP09737222.1A patent/EP2328903B1/fr active Active
- 2009-09-11 CA CA2736130A patent/CA2736130C/fr not_active Expired - Fee Related
- 2009-09-11 CN CN2009801456428A patent/CN102209721A/zh active Pending
- 2009-09-11 TW TW098130795A patent/TWI385175B/zh not_active IP Right Cessation
- 2009-09-11 EA EA201100461A patent/EA201100461A1/ru unknown
- 2009-09-11 WO PCT/US2009/056748 patent/WO2010030954A1/fr active Application Filing
- 2009-09-11 BR BRPI0918449A patent/BRPI0918449A2/pt not_active IP Right Cessation
- 2009-09-11 MY MYPI2011001092A patent/MY148558A/en unknown
-
2011
- 2011-02-27 IL IL211440A patent/IL211440A0/en unknown
- 2011-03-10 CL CL2011000516A patent/CL2011000516A1/es unknown
- 2011-03-14 CR CR20110134A patent/CR20110134A/es unknown
- 2011-03-25 CO CO11036742A patent/CO6362014A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02674A patent/ZA201102674B/en unknown
- 2011-04-11 MA MA33762A patent/MA32705B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2328903B1 (fr) | 2014-03-05 |
CL2011000516A1 (es) | 2011-08-26 |
CN102209721A (zh) | 2011-10-05 |
PE20110805A1 (es) | 2011-11-09 |
ZA201102674B (en) | 2011-12-28 |
TW201022280A (en) | 2010-06-16 |
IL211440A0 (en) | 2011-05-31 |
ES2459195T3 (es) | 2014-05-08 |
CR20110134A (es) | 2011-08-04 |
EA201100461A1 (ru) | 2011-10-31 |
MX2011002705A (es) | 2011-09-09 |
KR20110073511A (ko) | 2011-06-29 |
US8426447B2 (en) | 2013-04-23 |
BRPI0918449A2 (pt) | 2019-09-24 |
EP2328903A1 (fr) | 2011-06-08 |
MY148558A (en) | 2013-04-30 |
AU2009291602B2 (en) | 2013-02-14 |
CA2736130A1 (fr) | 2010-03-18 |
CA2736130C (fr) | 2014-01-14 |
JP5579720B2 (ja) | 2014-08-27 |
JP2012502112A (ja) | 2012-01-26 |
AU2009291602A1 (en) | 2010-03-18 |
WO2010030954A1 (fr) | 2010-03-18 |
TWI385175B (zh) | 2013-02-11 |
CO6362014A2 (es) | 2012-01-20 |
US20100087429A1 (en) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32705B1 (fr) | Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation | |
TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
MA29807B1 (fr) | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. | |
MX2009012608A (es) | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. | |
MX2012010658A (es) | Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa. | |
MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
MA34922B1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
TNSN06300A1 (fr) | Derives d'imidazole pour le traitement de troubles neurodegeneratifs | |
MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
MA27132A1 (fr) | Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues | |
MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
MA31857B1 (fr) | N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci | |
MA28241A1 (fr) | Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer | |
MA32506B1 (fr) | Nouveaux composes | |
MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
MA30037B1 (fr) | Compositions et procedes destines au traitement des troubles du snc | |
MA32374B1 (fr) | Composes comprenant un groupe cyclobutoxy | |
MA46342A (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
MA29989B1 (fr) | Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie |